Rate the Article: Will Dostarlimab Become the New Rectal Cancer Drug of Choice?, IJSR, Call for Papers, Online Journal
International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064

Downloads: 1 | Views: 276 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Informative Article | Pharmacotherapeutics | India | Volume 11 Issue 6, June 2022 | Rating: 4.3 / 10


Will Dostarlimab Become the New Rectal Cancer Drug of Choice?

Motupalli Sankeerth Kumar, Ponnaluri Lalitha, Seelam Victor John Wilson


Abstract: Information on a recent clinical trial in the United States on a drug that has been shown to be nearly 100% effective against rectal cancer in the sample population.


Keywords: Dostarlimab, Rectal cancer, new drug of choice


Edition: Volume 11 Issue 6, June 2022,


Pages: 1369 - 1369



Rate this Article


Select Rating (Lowest: 1, Highest: 10)

5

Your Comments (Only high quality comments will be accepted.)

Characters: 0

Your Full Name:


Your Valid Email Address:


Verification Code will appear in 2 Seconds ... Wait

Top